PepGen’s main strengths are its strong liquidity relative to debt, its focused and innovative EDO delivery platform, and encouraging early data in a high‑unmet‑need condition, DM1. The company has demonstrated the ability to raise equity capital to support its research, maintain a low‑leverage balance sheet, and pivot its strategy in response to clinical results, all of which are valuable attributes for a small biotech.

Key risks include the complete absence of revenue, large and growing operating and cash flow losses, and a heavy reliance on a single lead asset after discontinuing the DMD program. Future funding needs are likely, which raises the possibility of further dilution, and the competitive landscape in DM1 and oligonucleotide delivery is intense. Scientific, regulatory, and execution risks remain high, and failure to deliver convincing clinical results could significantly weaken both the financial position and the strategic story.

The outlook is highly dependent on clinical milestones and financing. If upcoming DM1 trials continue to show strong biomarker and, importantly, functional benefits with an acceptable safety profile, PepGen could move toward later‑stage development and potentially attract partnerships or less dilutive capital. If results disappoint or funding conditions tighten, the combination of high cash burn and a concentrated pipeline would become a major concern. Overall, PepGen sits at a typical but precarious stage for a clinical‑stage biotech: substantial upside if the science works, but considerable financial and execution risk until it does.